Abstract
Introduction:
Calcitonin Gene Related Peptide (CGRP) is a neuropeptide ubiquitous in the peripheral and central nervous
system, mostly known for the role in vasodilation and pain signal transmission during migraine attacks. Recent
studies have been unraveling its immunomodulatory properties, including its possible role in multiple sclerosis
(MS) pathophysiology, however there is no conclusive evidence on whether it plays a pro or anti-inflammatory
role.
Objectives/Aims:
To evaluate soluble CGRP levels at MS diagnosis, in cerebrospinal fluid (CSF) and serum, and evaluate
associations with progression and short-term disease severity.
Methods:
We enrolled for a retrospective cohort study 59 patients (39 females, mean age at diagnosis 38.79 years ±
standard deviation or SD 9.89) with Radiological Isolated Syndrome (RIS), Clinical Isolated Syndrome (CIS) and
Relapsing-Remitting (RR) MS. During the diagnostic work-up were collected clinic-demographic data, serum
and CSF. Patients were followed with clinical visits in which clinical data were collected.*** CGRP levels were
determined through an ELISA commercial kit (MyBioSource Inc, MBS267126, San Diego, CA, USA). None had a
history of migraine attack at diagnosis. Statistical analyses were conducted with STATA software to determine
Mann–Whitney, Kruskal-Wallis test and Spearman’s rank correlation coefficient significance.
Results:
CGRP levels were significantly higher in MS patients if compared to healthy controls published by Papiri et Al.
(PMID: 37013432) and Han et Al. (PMID: 35204700). Mean values resulted 73.10 pg/ml in serum (±9.42 vs
29.50 ± 8.91, p<0.05 t-test) and 64.01 in CSF (± 10.39 vs 52.05 ± 5.70, p<0.05 t-test). CGRP levels did not relate
to clinical variables at diagnosis: age, gender, Expanded Disability Status Scale (EDSS), number of T2,
gadolinium enhancing and spinal cord lesions. However, there was a positive correlation between serum CGRP
and the Multiple Sclerosis Severity Score (MSSS) at the last follow up (r2 = 0.27, p<0.05 Spearman’s rank
correlation).
Conclusion:
We observed an increased CGRP level in the CSF and serum of MS patients at diagnosis. Our findings suggest
its potential use as a biomarker to identify cases with poor prognosis, indicating a pro-inflammatory effect of
this neuropeptide.
Lingua originale | Inglese |
---|---|
Stato di pubblicazione | Pubblicato - 2023 |
Evento | ECTRIMS 2023 - Milano Durata: 1 gen 2023 → … |
???event.eventtypes.event.conference???
???event.eventtypes.event.conference??? | ECTRIMS 2023 |
---|---|
Città | Milano |
Periodo | 1/01/23 → … |
Keywords
- CGRP
- Multiple sclerosis
- neuroinflammation
- biomarker
- treatment